Performant Financial Corporation

NasdaqGS:PFMT Stock Report

Market Cap: US$268.6m

Performant Financial Valuation

Is PFMT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PFMT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PFMT ($3.56) is trading below our estimate of fair value ($25.2)

Significantly Below Fair Value: PFMT is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PFMT?

Other financial metrics that can be useful for relative valuation.

PFMT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA-72x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PFMT's PS Ratio compare to its peers?

The above table shows the PS ratio for PFMT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
BDSX Biodesix
4x19.7%US$245.3m
EHAB Enhabit
0.4x4.1%US$380.6m
VMD Viemed Healthcare
1.6x11.8%US$316.8m
AIRS AirSculpt Technologies
1.5x8.4%US$275.9m
PFMT Performant Financial
2.3x13.0%US$268.6m

Price-To-Sales vs Peers: PFMT is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (1.9x).


Price to Earnings Ratio vs Industry

How does PFMT's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.3%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.3%
n/an/an/a
No more companies

Price-To-Sales vs Industry: PFMT is expensive based on its Price-To-Sales Ratio (2.3x) compared to the US Healthcare industry average (1.2x).


Price to Sales Ratio vs Fair Ratio

What is PFMT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PFMT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.3x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: PFMT is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PFMT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.56
US$7.67
+115.4%
6.1%US$8.00US$7.00n/a3
Sep ’25US$3.53
US$7.67
+117.2%
6.1%US$8.00US$7.00n/a3
Aug ’25US$3.62
US$7.67
+111.8%
6.1%US$8.00US$7.00n/a3
Jul ’25US$2.66
US$7.50
+182.0%
6.7%US$8.00US$7.00n/a2
Jun ’25US$3.07
US$7.50
+144.3%
6.7%US$8.00US$7.00n/a2
May ’25US$2.76
US$7.50
+171.7%
6.7%US$8.00US$7.00n/a2
Apr ’25US$2.66
US$7.50
+182.0%
6.7%US$8.00US$7.00n/a2
Mar ’25US$2.94
US$7.50
+155.1%
6.7%US$8.00US$7.00n/a2
Feb ’25US$2.91
US$7.50
+157.7%
6.7%US$8.00US$7.00n/a2
Jan ’25US$3.13
US$7.50
+140.0%
6.7%US$8.00US$7.00n/a2
Dec ’24US$3.01
US$7.50
+149.2%
6.7%US$8.00US$7.00n/a2
Nov ’24US$2.21
US$7.50
+240.1%
6.7%US$8.00US$7.00n/a2
Oct ’24US$2.26
US$7.50
+231.9%
6.7%US$8.00US$7.00US$3.542
Sep ’24US$2.44
US$7.50
+207.4%
6.7%US$8.00US$7.00US$3.532
Aug ’24US$3.04
US$7.50
+146.7%
6.7%US$8.00US$7.00US$3.622
Jul ’24US$2.70
US$7.50
+177.8%
6.7%US$8.00US$7.00US$2.662
Jun ’24US$2.61
US$7.50
+187.4%
6.7%US$8.00US$7.00US$3.072
May ’24US$3.19
US$7.50
+135.1%
6.7%US$8.00US$7.00US$2.762
Apr ’24US$3.40
US$7.50
+120.6%
6.7%US$8.00US$7.00US$2.662
Mar ’24US$3.23
US$7.50
+132.2%
6.7%US$8.00US$7.00US$2.942
Feb ’24US$3.20
US$7.50
+134.4%
6.7%US$8.00US$7.00US$2.912
Jan ’24US$3.61
US$7.50
+107.8%
6.7%US$8.00US$7.00US$3.132
Dec ’23US$2.40
US$7.50
+212.5%
6.7%US$8.00US$7.00US$3.012
Nov ’23US$2.33
US$7.50
+221.9%
6.7%US$8.00US$7.00US$2.212
Oct ’23US$1.85
US$7.50
+305.4%
6.7%US$8.00US$7.00US$2.262

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies